These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 31417682)

  • 21. Changes in List Prices, Net Prices, and Discounts for Branded Drugs in the US, 2007-2018.
    Hernandez I; San-Juan-Rodriguez A; Good CB; Gellad WF
    JAMA; 2020 Mar; 323(9):854-862. PubMed ID: 32125403
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Determinants of branded prescription medicine prices in OECD countries.
    Kanavos PG; Vandoros S
    Health Econ Policy Law; 2011 Jul; 6(3):337-67. PubMed ID: 21676345
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Availability of generic drugs in the public sector and prices in the private sector in different regions of Brazil].
    Miranda ES; Pinto Cdu B; dos Reis AL; Emmerick IC; Campos MR; Luiza VL; Osorio-de-Castro CG
    Cad Saude Publica; 2009 Oct; 25(10):2147-58. PubMed ID: 19851615
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The impact of Chinese volume-based procurement on pharmaceutical market concentration.
    Yang Y; Liu Y; Mao Z; Mao J; Jin Y
    Front Pharmacol; 2024; 15():1386533. PubMed ID: 38895618
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of budget savings from patent expiration of cancer drugs to improve affordability and accessibility.
    Lee SM; Kim HJ; Suh D; Joung KI; Kim ES; Back HJ; Kwon JY; Park MJ; Suh DC
    BMC Health Serv Res; 2021 Feb; 21(1):126. PubMed ID: 33549099
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Variation in Price of Cardiovascular and Diabetes Medicine in Indonesia, and Relationship with Quality: A Mixed Methods Study in East Java.
    Pisani E; Dewi A; Palagyi A; Praveen D; Ihsan BRP; Lawuningtyas Hariadini A; Lyrawati D; Sujarwoto ; Maharani A; Tampubolon G; Patel A
    Am J Trop Med Hyg; 2023 Jun; 108(6):1287-1299. PubMed ID: 37160275
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Patent Cliffs in the Era of Complex Therapies and Biologics.
    Sabatini MT; Silva M
    Pharmaceut Med; 2020 Aug; 34(4):271-278. PubMed ID: 32772314
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Is the Brazilian pharmaceutical policy ensuring population access to essential medicines?
    Bertoldi AD; Helfer AP; Camargo AL; Tavares NU; Kanavos P
    Global Health; 2012 Mar; 8():6. PubMed ID: 22436555
    [TBL] [Abstract][Full Text] [Related]  

  • 29. European countries with small populations can obtain low prices for drugs: Lithuania as a case history.
    Garuoliene K; Godman B; Gulbinovič J; Wettermark B; Haycox A
    Expert Rev Pharmacoecon Outcomes Res; 2011 Jun; 11(3):343-9. PubMed ID: 21671703
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The impact of the national volume-based procurement policy on the use of policy-related drugs in Nanjing: an interrupted time-series analysis.
    Wang X; He X; Zhang P; Zhang M; Ma R; Dai R; Li X
    Int J Equity Health; 2023 Sep; 22(1):200. PubMed ID: 37770924
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Suboptimal prescribing behaviour associated with clinical software design features: a retrospective cohort study in English NHS primary care.
    MacKenna B; Curtis HJ; Walker AJ; Bacon S; Croker R; Goldacre B
    Br J Gen Pract; 2020 Sep; 70(698):e636-e643. PubMed ID: 32784218
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An analysis of orphan medicine expenditure in Europe: is it sustainable?
    Mestre-Ferrandiz J; Palaska C; Kelly T; Hutchings A; Parnaby A
    Orphanet J Rare Dis; 2019 Dec; 14(1):287. PubMed ID: 31829218
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Early achievements of the Danish pharmaceutical industry-7].
    Grevsen JV; Kirkegaard H; Kruse E; Kruse PR
    Theriaca; 2014; (42):31-62. PubMed ID: 25816561
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An analysis of volumes, prices and pricing trends of the pediatric antiretroviral market in developing countries from 2004 to 2012.
    Lee JSF; Sagaon Teyssier L; Dongmo Nguimfack B; Collins IJ; Lallemant M; Perriens J; Moatti JP
    BMC Pediatr; 2016 Mar; 16():41. PubMed ID: 26979974
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Farmácia Popular Program: pharmaceutical market analysis of antihypertensive acting on the renin-angiotensin system medicines.
    Silva RMD; Chaves GC; Chaves LA; Campos MR; Luiza VL; Bertoldi AD; Ross-Degnan D; Emmerick ICM
    Cien Saude Colet; 2017 Aug; 22(8):2501-2512. PubMed ID: 28793067
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Increased topical generic prices by manufacturers.
    Bhatt MD; Bhatt BD; Dorrian JT; McLellan BN
    J Am Acad Dermatol; 2019 May; 80(5):1353-1357. PubMed ID: 29544742
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluating drug prices, availability, affordability, and price components: implications for access to drugs in Malaysia.
    Babar ZU; Ibrahim MI; Singh H; Bukahri NI; Creese A
    PLoS Med; 2007 Mar; 4(3):e82. PubMed ID: 17388660
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evolutions in both co-payment and generic market share for common medication in the Belgian reference pricing system.
    Fraeyman J; Verbelen M; Hens N; Van Hal G; De Loof H; Beutels P
    Appl Health Econ Health Policy; 2013 Oct; 11(5):543-52. PubMed ID: 24062144
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Effect of Market Competition on the Price of Topical Eye Drops.
    Watane A; Kalavar M; Reyes J; Yannuzzi NA; Sridhar J
    Semin Ophthalmol; 2022 Jan; 37(1):42-48. PubMed ID: 33780301
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Trade agreements and drug access: assessment of the impact of the 2009 Peruvian new drug policy on anti-infectives registration and availability.
    Araujo L; Montagne M
    J Pharm Policy Pract; 2018; 11():24. PubMed ID: 30338072
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.